Start here if you're new
what it is
Alaunos makes experimental T-cell therapies for solid tumors.
how it gets paid
Last year Alaunos Therapeutic made $10K in revenue. Library TCR-T Cell Therapy was the main engine at $4K, or 40% of sales.
what just happened
Alaunos posted $2K in quarterly revenue and lost $1.84 a share.
At a glance
C+ balance sheet — struggling to keep the lights on
5/100 earnings predictability — expect surprises
-$2.92 fy2024 eps est
$0M fy2024 rev est
n/a operating margin
xvary composite: 16/100 — weak
What they do
Alaunos makes experimental T-cell therapies for solid tumors.
You are not buying scale. You are buying a 12-TCR library aimed at KRAS, TP53, and EGFR tumors. That is 12 shots on goal against cancers where one working therapy matters more than sales today. The absurd part is the contrast: 12 targets, 1 employee, and a public stock price.
How they make money
$10K
annual revenue
Library TCR-T Cell Therapy
$4K
hunTR discovery engine
$2K
Sleeping Beauty Gene Transfer Platform
$2K
Research collaborations
$1K
Other
$1K
The products that matter
preclinical oncology research
TCR-T Cell Therapy Platform
only disclosed pipeline asset in this snapshot
It is the whole story. As of the March 2026 8-K reference, there was no clinical data reported here, which is a thin foundation for a $7.8M equity value.
single-asset risk
Key numbers
$10K
annual revenue
That is the whole sales engine. For a public company, $10K is basically a typo.
1
employees
One employee means you are betting on a skeleton crew, not an operating machine.
12
tcrs
Twelve targets are in Phase I/II work. More shots on goal help, but none are proven yet.
0.2
beta
Low beta means the stock moved less than the market in the past. That does not save you from dilution.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for TCRT right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Alaunos posted $2K in quarterly revenue and lost $1.84 a share.
That is the kind of quarter that reminds you this is a research story, not a sales story. Annual revenue was $10K, so the company is still running on science and funding, not demand.
$2K
revenue
-$1.84
eps
235.0%
eps vs. last year
the number that mattered
Quarterly revenue was $2K, and that is smaller than some invoice errors. You are looking at a company where the science matters more than sales.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk is failure or delay of the lone TCR-T oncology program. With one preclinical asset and only $6K in revenue, there is no second engine if the first one stalls.
med
single-asset clinical risk
The company is built around one preclinical platform. As presented here, there is no clinical data to diversify that bet or reduce the binary nature of the story.
Impact: if the asset disappoints, the equity case can collapse with it because there is no meaningful revenue base to catch the fall.
med
financing and dilution
The company posted a $4.0M trailing loss and investors sought a $7M private placement in February 2026. That proposed financing is nearly the size of the current market cap.
Impact: when the capital raise is roughly the same scale as the equity value, existing holders can get diluted fast or subordinated by new terms.
med
governance churn
An 8-K on January 8, 2026 disclosed management changes, and February 2026 featured a push tied to board control. For a microcap biotech, governance instability is operational risk wearing a suit.
Impact: when leadership and board structure are in motion, strategic continuity gets weaker right when the company needs capital and scientific credibility.
A $4.0M loss on $6K in revenue means the combined risk picture is simple: this company needs capital, data, or both before the market stops treating it like a binary ticket.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
march 10, 2026 earnings date
This is the next scheduled filing date in the snapshot. Ignore the usual small-cap EPS theater and watch for any update on cash needs, strategic direction, or pipeline progress.
financing risk
whether the $7M private placement becomes real
A financing request that is nearly the size of a $7.8M market cap can change ownership economics fast. This is the capital event that matters most.
pipeline
any move from preclinical language to actual data
The March 2026 8-K reference still leaves this page without clinical data. If that changes, the stock's entire probability tree changes with it.
balance sheet
whether the 3.5x current ratio starts shrinking
Current ratio is short-term assets divided by short-term liabilities. It looks fine today. If it deteriorates while losses persist, the financing clock gets louder.
Analyst rankings
earnings predictability
5 / 100
In human-speak, analysts do not have a stable business model to forecast here. Expect discontinuity, not consistency.
beta
0.2
Beta measures how a stock moves versus the market. On a microcap like this, a low beta is less a badge of safety than a reminder that standard market correlations barely explain the trading.
source: institutional data
Institutional activity
institutional ownership data for TCRT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive